Can a Gene-Targeting drug stop SMA before it starts?

NCT ID NCT07221669

First seen Oct 31, 2025 · Last updated May 12, 2026 · Updated 26 times

Summary

This study tests a drug called salanersen in babies who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The drug aims to help the body make more of a protein needed for muscle and nerve function. Researchers want to see if early treatment can help babies reach normal motor milestones like sitting and walking.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCULAR ATROPHY, SPINAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Childrens Hospital of the Kings Daughter Norfolk

    RECRUITING

    Norfolk, Virginia, 23507, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

  • Neurology Rare Disease Center

    RECRUITING

    Flower Mound, Texas, 75028, United States

    Contact Phone: •••-•••-••••

    Contact

Conditions

Explore the condition pages connected to this study.